abstract |
The present invention relates to novel formulations of soluble Fc receptors and particularly to formulations containing a high concentration of soluble FcγRIIB receptor. In addition, the present invention relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infectious diseases, and other conditions accompanied by the immune system. |